



PTO/SB-08a/b (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/534651		
		Filing Date	May 12, 2005		
		First Named Inventor	Rodney Brian Hargreaves		
		Art Unit	1615		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	4	Attorney Docket Number	ASZD-P01-898

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>TD</i>	AA*	US-6,613,942	09-02-2003	<i>Ling et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code*	Number-Kind Code* (if known)			
<i>TD</i>	BA	WO-00/028202-A1		05-11-2000	Pharmacia & Upjohn S.P.A.	
	BB	WO-00/58293-A1		10-05-2000	F. Hoffmann-La Roche AG	
	BC	WO-01/20327-A1		03-22-2001	AstraZeneca AB	
	BD	WO-01/44216-A1		06-21-2001	F. Hoffman-La Roche AG	
	BE	WO-01/83465-A2		11-08-2001	F. Hoffman-La Roche AG	
	BF	WO-01/83476-A2		11-08-2001	F. Hoffman-La Roche AG	
	BG	WO-01/85706-A1		11-15-2001	F. Hoffman-La Roche AG	
	BH	WO-01/85707-A1		11-15-2001	F. Hoffman-La Roche AG	
	BI	WO-02/00633-A1		01-03-2002	Tularik Inc.	
	BJ	WO-02/024682-A1		03-28-2002	Janssen Pharmaceutica N.V.	
	BK	WO-02/064545-A1		08-22-2002	Aventis Pharma Deutschland GMBH	
	BL	WO-02/08209-A1		01-31-2002	F. Hoffman-La Roche AG	
	BM	WO-02/14312-A1		02-21-2002	F. Hoffman-La Roche AG	
	BN	WO-02/46173-A1		06-13-2002	F. Hoffman-La Roche AG	
	BO	WO-02/48106-A2		08-20-2002	F. Hoffman-La Roche AG	
	BP	WO-03/000262-A1		01-03-2003	AstraZeneca AB	
	BQ	WO-03/000267-A1		01-03-2003	AstraZeneca AB	
	BR	WO-03/015774-A1		02-27-2003	AstraZeneca AB	
	BS	WO-03/022856-A1		03-20-2003	Pharmacia & Upjohn Company	
	BT	WO-03/028641-A2		04-10-2003	Taisho Pharmaceutical Co., Ltd.	
	BU	WO-03/047626-A1		06-12-2003	Novo Nordisk A/S	
	BV	WO-03/048152-A2		06-12-2003	Tularik Inc.	
	BW	WO-03/055482-A1		07-10-2003	Novo Nordisk A/S	
	BX	WO-03/080585-A1		10-02-2003	Banyu Pharmaceutical Co., Ltd.	
	BY	WO-03/082838 A1		10-09-2003	Shanghai Institute of Materia Medica	
	BZ	WO-03/095438-A1		11-20-2003	F. Hoffman-La Roche AG	
	BA1	WO-03/097824-A1		11-27-2003	Banyu Pharmaceutical Co., Ltd.	
	BB1	WO-04/002481-A1		01-08-2004	Novo Nordisk A/S	
	BC1	WO-04/045614-A1		06-03-2004	AstraZeneca AB	
	BD1	WO-04/046139-A1		06-03-2004	AstraZeneca AB	
	BE1	WO-04/050845-A1		06-17-2004	Novartis AG	
	BF1	WO-04/052869-A1		06-24-2004	F. Hoffman-La Roche AG	
	BG1	WO-04/063179-A1		07-29-2004	Eli Lilly and Company	
	BH1	WO-04/063194-A1		07-29-2004	Eli Lilly and Company	
Examiner Signature	<i>TD</i>			Date Considered	3/17/2006	